Company News: Gilead Sciences, Cubist Pharmaceuticals and Calixa Therapeutics
Gilead Sciences said that it will likely end development of darusentan, a once promising endothelin receptor antagonist for treating resistant ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.